Effects of Escitalopram on the Sleep EEG Power in Patients With Major Depressive Disorder

• Status: Completed
• Trial end date: 2018-12-30
• Target enrollment: 0
• Participant gender: Male

Summary

The main objective was to compare the differences of PSG parameters and plasma melatonin levels before and after treatment with escitalopram for 8 weeks. Polysomnography (PSG) was detected over a night and blood samples were collected at 4 h intervals for 24 h from 13 male healthy controls and 13 male MDD patients before and after treatment with escitalopram for 8 weeks. The outcome measures included the levels of plasma melatonin, PSG parameters (include sleep architecture and power analysis) and scales.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Peking University Sixth Hospital
• Collaborator: National Institute on Drug Dependence, China
• Treatments: Citalopram; Dexetimide

Criteria

Inclusion Criteria:

1. Clinical diagnosis of MDD;

2. Hamilton Rating Scale for Depression 17-items (HRSD-17) total scores ≥ 22;

3. Male patients aged between 18 and 45 years

Exclusion Criteria:

1. Significant suicide risk by HRSD suicide scores > 2;

2. Accompanied with psychiatric symptoms;

3. Treated with MECT within 6 months.